GW Pharmaceuticals, a pharmaceutical company in Great Britain, is presently examining Sativex, which is distributed as a mouth spray, in medical tests. GW Pharmaceuticals seeks the approval of the United States FDA (Food and Drug Administration) for Sativex to be a cancer pain treatment once the tests are finished, possibly within 2014.
The mouth spray’s active ingredients, called as cannabinoids, came from a cannabis plant. Sativex is the primary marijuana-based treatment to be formulated by extracting the ingredients from cannabis, instead of synthesizing it. Cesamot and Marinol are the other two drugs that obtained the approval of FDA which are derived from synthetic cannabinoids.
Since the drug has THC, the compound mainly accountable for making the users of marijuana “high”, it is likely that the public would utilize Sativex for recreational purposes instead of medical reasons.
Dr. Jeffrey Bernstein, Florida Poison Information Center’s director at the University of Miami Miller School of Medicine, said that the public will certainly abuse Sativex.
On the other hand, since Sativex is distributed through ingestion, instead of smoking, it’s “highness” effect is much longer than smoking marijuana.
Login
Recent News
vBulletin Message